559 related articles for article (PubMed ID: 9486654)
1. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
[TBL] [Abstract][Full Text] [Related]
2. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
3. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
4. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
5. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
Jeanteur P
Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
[TBL] [Abstract][Full Text] [Related]
6. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
[TBL] [Abstract][Full Text] [Related]
7. Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo.
Tomita A; Buchholz DR; Obata K; Shi YB
J Biol Chem; 2003 Aug; 278(33):30788-95. PubMed ID: 12794076
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo.
Atsumi A; Tomita A; Kiyoi H; Naoe T
Biochem Biophys Res Commun; 2006 Jul; 345(4):1471-80. PubMed ID: 16730330
[TBL] [Abstract][Full Text] [Related]
10. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia.
Hong SH; David G; Wong CW; Dejean A; Privalsky ML
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9028-33. PubMed ID: 9256429
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
12. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
[TBL] [Abstract][Full Text] [Related]
13. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.
Matsushita H; Scaglioni PP; Bhaumik M; Rego EM; Cai LF; Majid SM; Miyachi H; Kakizuka A; Miller WH; Pandolfi PP
J Exp Med; 2006 Apr; 203(4):821-8. PubMed ID: 16549595
[TBL] [Abstract][Full Text] [Related]
14. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
Dong S; Tweardy DJ
Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation in acute promyelocytic leukemia.
Lin RJ; Sternsdorf T; Tini M; Evans RM
Oncogene; 2001 Oct; 20(49):7204-15. PubMed ID: 11704848
[TBL] [Abstract][Full Text] [Related]
16. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
Zhou DC; Kim SH; Ding W; Schultz C; Warrell RP; Gallagher RE
Blood; 2002 Feb; 99(4):1356-63. PubMed ID: 11830487
[TBL] [Abstract][Full Text] [Related]
17. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
19. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
[TBL] [Abstract][Full Text] [Related]
20. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
